NasdaqCM:SLNO

Stock Analysis Report

Executive Summary

Soleno Therapeutics, Inc. focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases.

Snowflake

Fundamentals

Adequate balance sheet with moderate growth potential.

Share Price & News

How has Soleno Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SLNO's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

6.4%

SLNO

1.1%

US Biotechs

0.9%

US Market


1 Year Return

-25.1%

SLNO

9.1%

US Biotechs

15.5%

US Market

Return vs Industry: SLNO underperformed the US Biotechs industry which returned 9.1% over the past year.

Return vs Market: SLNO underperformed the US Market which returned 15.5% over the past year.


Shareholder returns

SLNOIndustryMarket
7 Day6.4%1.1%0.9%
30 Day0.7%10.4%4.7%
90 Day-24.7%5.8%6.6%
1 Year-25.1%-25.1%10.1%9.1%18.1%15.5%
3 Year-69.3%-69.3%16.0%12.3%48.0%38.5%
5 Year-92.0%-92.0%4.5%-0.4%62.1%44.2%

Price Volatility Vs. Market

How volatile is Soleno Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Soleno Therapeutics undervalued compared to its fair value and its price relative to the market?

3.18x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SLNO's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate SLNO's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SLNO is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: SLNO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SLNO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SLNO is overvalued based on its PB Ratio (3.2x) compared to the US Biotechs industry average (2.8x).


Next Steps

Future Growth

How is Soleno Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

75.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SLNO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.7%).

Earnings vs Market: SLNO is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: SLNO's is expected to become profitable in the next 3 years.

Revenue vs Market: Insufficient data to determine if SLNO's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if SLNO's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SLNO's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Soleno Therapeutics performed over the past 5 years?

-2.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SLNO has high quality earnings.

Growing Profit Margin: SLNO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SLNO is unprofitable, and losses have increased over the past 5 years at a rate of -2.5% per year.

Accelerating Growth: Unable to compare SLNO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SLNO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (86.5%).


Return on Equity

High ROE: SLNO has a negative Return on Equity (-105.85%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Soleno Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: SLNO's short term assets ($11.6M) exceeds its short term liabilities ($3.5M)

Long Term Liabilities: SLNO's short term assets ($11.6M) exceeds its long term liabilities (10.4M)


Debt to Equity History and Analysis

Debt Level: SLNO is debt free.

Reducing Debt: SLNO currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Inventory Level: SLNO has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if SLNO's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SLNO has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if SLNO has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Soleno Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate SLNO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate SLNO's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SLNO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SLNO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SLNO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Soleno Therapeutics's salary, the management and board of directors tenure and is there insider trading?

3.5yrs

Average management tenure


CEO

Anish Bhatnagar (49yo)

5.8yrs

Tenure

US$951,911

Compensation

Dr. Anish Bhatnagar, M.D. has been the Chief Executive Officer of Soleno Therapeutics, Inc. since February 6, 2014, President since December 31, 2013. Dr. Bhatnagar has been Director at Soleno Therapeutics ...


CEO Compensation Analysis

Compensation vs Market: Anish's total compensation ($USD951.91K) is above average for companies of similar size in the US market ($USD509.77K).

Compensation vs Earnings: Anish's compensation has been consistent with company performance over the past year.


Management Age and Tenure

3.5yrs

Average Tenure

58.5yo

Average Age

Experienced Management: SLNO's management team is considered experienced (3.5 years average tenure).


Board Age and Tenure

5.4yrs

Average Tenure

59yo

Average Age

Experienced Board: SLNO's board of directors are considered experienced (5.4 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellUS$150,38715 Nov 19
Vivo Capital, LLC
EntityCompany
Shares97,024
Max PriceUS$1.55
SellUS$13,58407 Nov 19
Vivo Capital, LLC
EntityCompany
Shares8,764
Max PriceUS$1.55
SellUS$524,78704 Nov 19
Vivo Capital, LLC
EntityCompany
Shares334,417
Max PriceUS$1.58
BuyUS$2,760,00029 Oct 19
Abingworth LLP
EntityCompany
Shares2,300,000
Max PriceUS$1.20
BuyUS$2,760,00029 Oct 19
Abingworth LLP
EntityCompany
Shares2,300,000
Max PriceUS$1.20
SellUS$48,51428 Oct 19
Vivo Capital, LLC
EntityCompany
Shares30,547
Max PriceUS$1.60
BuyUS$122,27630 Jul 19
Oracle Investment Management, Inc.
EntityCompany
Shares57,069
Max PriceUS$2.14
SellUS$174,90622 May 19
Vivo Capital, LLC
EntityCompany
Shares90,724
Max PriceUS$1.98
BuyUS$159,39218 Mar 19
Oracle Investment Management, Inc.
EntityCompany
Shares130,363
Max PriceUS$1.22
BuyUS$7,470,83527 Dec 18
Abingworth LLP
EntityCompany
Shares4,669,272
Max PriceUS$1.60
BuyUS$4,868,69927 Dec 18
Jack Schuler
EntityIndividual
Shares3,031,002
Max PriceUS$1.61
BuyUS$2,000,06021 Dec 18
Oracle Investment Management, Inc.
EntityCompany
Shares1,245,135
Max PriceUS$1.61

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 61.7%.


Management Team

  • Jon Wolter (69yo)

    CFO & Principal Accounting Officer

    • Tenure: 2.2yrs
    • Compensation: US$288.00k
  • Anish Bhatnagar (49yo)

    President

    • Tenure: 5.8yrs
    • Compensation: US$951.91k
  • David O'Toole (60yo)

    Consultant

    • Tenure: 2.2yrs
    • Compensation: US$358.00k
  • Neil Cowen

    Senior Vice President of Drug Development

    • Tenure: 0yrs
  • Tony Wondka (57yo)

    Senior Vice President of Research & Development

    • Tenure: 4.8yrs
    • Compensation: US$270.00k
  • Patricia Hirano

    Head of Regulatory Affairs and Quality

    • Tenure: 0yrs

Board Members

  • Ernie Mario (80yo)

    Independent Chairman

    • Tenure: 5.8yrs
    • Compensation: US$83.83k
  • Bill Harris (61yo)

    Independent Director

    • Tenure: 5.4yrs
    • Compensation: US$75.94k
  • Stuart J. Collinson (59yo)

    Independent Director

    • Tenure: 2.7yrs
    • Compensation: US$60.91k
  • Thomas Casale

    Member of Advisory Board

    • Tenure: 0yrs
  • Andrew Sinclair (47yo)

    Independent Director

    • Tenure: 0.9yrs
    • Compensation: US$20.23k
  • Anish Bhatnagar (49yo)

    President

    • Tenure: 5.8yrs
    • Compensation: US$951.91k
  • Robert Christensen

    Member of Advisory Board

    • Tenure: 0yrs
  • Vinny Bhutani

    Member of Advisory Board

    • Tenure: 0yrs
  • Glenis Scadding

    Member of Advisory Board

    • Tenure: 0yrs
  • David Stevenson

    Member of Advisory Board

    • Tenure: 0yrs

Company Information

Soleno Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Soleno Therapeutics, Inc.
  • Ticker: SLNO
  • Exchange: NasdaqCM
  • Founded: 1999
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$66.541m
  • Shares outstanding: 44.66m
  • Website: https://www.soleno.life

Number of Employees


Location

  • Soleno Therapeutics, Inc.
  • 1235 Radio Road
  • Suite 110
  • Redwood City
  • California
  • 94065
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SLNONasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDNov 2014
6XC1BST (Boerse-Stuttgart)YesCommon StockDEEURNov 2014
6XC1DB (Deutsche Boerse AG)YesCommon StockDEEURNov 2014

Biography

Soleno Therapeutics, Inc. focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, Diazoxide Choline Controlled Release (DCCR ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/19 00:42
End of Day Share Price2019/11/18 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.